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| INTRODUC TI ON
Esophageal cancer is a highly aggressive disease with poor prognosis. According to the latest global cancer statistics, each year, an estimated 455 800 new esophageal cancer cases and 400 200 deaths occur globally. In males, it is the seventh most prevalent and sixth most highly mortal cancer, whereas in females it is the ninth most common cause of mortality.
1
Numerous prognostic factors, including TNM stage, have been reported. 2 However, recently, inflammatory and nutritional markers such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and C-reactive protein to albumin ratio (CAR) have been recognized as useful prognostic markers for esophageal cancer patients worldwide. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Of note, the majority of these investigations were retrospective cohort studies. Only a few carried out a systematic review and meta-analysis. As a consequence, the consistency and magnitude of the prognostic impact of these markers currently remain unclear. Additionally, a systematic review and meta-analysis including CAR in esophageal cancer have not been carried out to date.
As a consequence, we carried out a systematic review and metaanalysis to assess the prognostic values of NLR, PLR, and CAR for esophageal cancer.
| MATERIAL S AND ME THODS

| Search strategy
In the present study, the search strategy was based on the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses and "platelet to lymphocyte ratio (or PLR)," and "esophageal cancer (or carcinoma)" and "C-reactive protein to albumin ratio (or CAR)."
Furthermore, references in the cited articles were overlooked. A total of 341 manuscripts were identified, and 331 manuscripts were excluded according to our exclusion criteria. (Figure 1 ).
| Inclusion and exclusion criteria
Inclusion criteria for selecting the articles for our analysis were as follows: (i) diagnosis of esophageal cancer was made based on pathological examination; (ii) correlation of pretreatment NLR, PLR, and CAR with overall survival (OS) was reported; (iii) publications were in English language. Exclusion criteria were as follows: only stage II or III was selected (n = 1); survival outcomes were not mentioned (n = 1); other topic (n = 3); cross-over design (n = 3); only basaloid cell squamous cell carcinoma was selected (n = 1); and unable to extract data (n = 1).
| Data extraction and quality evaluation
Two authors (Y.I. and H.T.) independently evaluated and extracted all candidate studies. Quality of the included studies was assessed through the Newcastle-Ottawa Quality Assessment Scale (NOS).
The latter consists of three parts as follows: selection, compatibility, and outcome assessments. 21 Maximum score was 9 points and a NOS score >5 indicated acceptable quality studies.
| Statistical analysis
Hazard ratio (HR) and 95% confidence interval (CI) for OS were directly summarized from each published study. We measured heterogeneity between the included studies using Cochran's Q test 
| Risk of bias
Appropriateness of the included studies was assessed by two authors (Y.I. and H.T.) by means of the Quality in Prognostic Studies (QUIPS) tool. 25 All studies were scored as low, moderate, or high risk.
Each included the following six domains: study participation, study attrition, prognostic factor measurement, outcome measurement, study confounding, and statistical analysis and reporting.
| RE SULTS
Flow diagram of the search strategy for the included studies is shown in Figure 1 . A total of 341 articles were identified in the databases. Subsequently, in line with the inclusion and exclusion criteria, 10 retrospective cohort studies (n = 4551 patients with esophageal cancer) were included in the present meta-analysis (Table 1) .
| Neutrophil to lymphocyte ratio
As shown in Figure 2 Abbreviations: CAR, C-reactive protein to albumin ratio; CSS, cancer-specific survival; DFS, disease-free survival; NA, not applicable; NLR, neutrophil to lymphocyte ratio; NOS, Newcastle-Ottawa Quality Assessment Scale; OS, overall survival; PLR, platelet to lymphocyte ratio; SCC, squamous cell carcinoma.
esophageal cancer with higher pretreatment NLR had a significant association with poorer prognosis in (HR 1.47, 95% CI = 1.32-1.63, P < .00001). As heterogeneity was not significant, the analysis was estimated using a fixed-effects model (P = .1, I 2 = 40%; Figure 2 ).
We observed that a higher NLR was significantly associated with male gender (OR 1.6, 95% CI = 1.13-2.27, P = .008) and T3 or T4 of tumor depth (OR 2.28, 95% CI = 1.67-3.11, P < .00001; Table 2 ).
In contrast, age, tumor location, tumor differentiation, and lymph node metastasis were not associated with higher NLR. OS subgroup analysis was carried out using histology, curative resection, cut-off value, sample size, and HR from multivariate analysis (Table S1 ). All subgroups with the exception of small sample size, strengthened the prognostic value of NLR for OS.
| Platelet to lymphocyte ratio
Platelet to lymphocyte ratio was reported in seven studies (n = 2655 patients), and the cut-off value of the included studies ranged from 135 to 244 (median, 157.4). Results of the meta-analysis show an absence of association between PLR and OS ( Figure 3 ). Due to significant heterogeneity, the analysis was carried out with a randomeffects model (P = .03, I 2 = 58%). We observed that a higher PLR was strongly associated with deeper tumor depth (OR 1.57, 95% CI = 1.29-1.90, P < .00001). In contrast, PLR was not associated with gender, age, lymph node metastasis, tumor differentiation, and main tumor location (Table 3) . OS subgroup analysis was done using histology, cut-off value, sample size, and HR from multivariate analysis (Table S2 ). PLR could not indicate a prognostic value for OS in any of the subgroups.
| C-reactive protein to albumin ratio
Only three studies (n = 1033 patients) evaluated the prognostic value of CAR. The cut-off value of the included studies ranged from 0.085 to 0.5 (median, 0.22). Higher CAR was strongly associated with poorer survival versus lower CAR groups (HR 1.88, 95%
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Link between clinicopathological features and elevated NLR CI = 1.28-2.77, P = .001). (Figure 4) A random-effects model for significant heterogeneity was used to carry out the analysis (P = .03, 
| Publication bias
Begg's funnel plots were used to visually assess the publication bias in the present study. (Figure S1 ) A significant publication bias was found in NLR for OS, as the funnel plots of NLR were asymmetrical. No obvious publication bias was found in PLR and CAR for OS, although there were a relatively small number of included studies.
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Forest plot for the association between C-reactive protein to albumin ratio (CAR) and overall survival of patients treated by surgery for esophageal cancer TA B L E 3 Link between clinicopathological features and elevated PLR
| Risk of bias
Risk of bias summary and graph using the QUIPS tool are described ( Figure S2A,B) . A lower risk of bias was present in study participation, study attrition, prognostic factor measurement, outcome measurement, and statistical analysis and reporting. However, in the study-confounding section, 40% of the high-risk studies were included.
6,13,16,17
| D ISCUSS I ON
Predicting prognosis using preoperative factors should be pivotal in determining perioperative treatment strategy. TNM tumor staging has been recognized to have the most predictive power for prognosis; however, it is well known that preoperative staging is not always consistent with postoperative staging.
26
In recent years, the influence of systemic inflammatory responses on the short-and long-term outcomes of various malignancies has been widely recognized. 27 Immune-inflammatory measures (eg, NLR, PLR, and CAR) are easily obtained from peripheral blood tests and have been widely recognized as significant prognostic markers in solid tumors such as gastric, [28] [29] [30] [31] colorectal, 32-34 liver, 35 and lung 36,37 cancers.
In esophageal cancer, there are currently a few systematic reviews and meta-analyses of immune-inflammatory measures as prognostic factors. 38 In the present study, we investigated and summarized the prognostic powers of NLR, PLR, and CAR for esophageal cancer using meta-analysis. Results of the meta-analysis showed a strong association between poor prognosis and high pretreatment NLR and CAR. However, PLR was not a significant prognostic marker for OS, which was not consistent with the result of a meta-analysis by Yodying et al 38 We speculated the reasons for these conflicting results as follows. Unlike NLR and CAR, many studies showed less impact of PLR on the prognosis than the other immune-inflammatory markers in various malignancies, including esophageal cancer. [39] [40] [41] [42] [43] [44] We previously reported that NLR and CAR were significant prognostic measures in esophageal cancer. On the contrary, similar to the current meta-analysis, PLR did not play the same role in esophageal cancer. 17 Interestingly, we previously reported that patients who did not undergo antiplatelet or anticoagulant therapy and who had a higher PLR value had a significantly poorer OS versus those with a lower PLR. However, such differences were not observed in patients who received antiplatelet and/or anticoagulant therapies.
Of the studies included in the present meta-analysis, none has de- Second, all studies were retrospective investigations, and clinicopathologically detailed covariates were not adequately adjusted. A high risk of bias regarding study confounding affected nearly half of the included studies. As a consequence, higher quality studies focusing on these confounding factors or prospectively carried out studies are needed. Third, the optimal cut-off values for each immune-inflammatory measure are still under debate. Seven studies used time-dependent receiver operating characteristics curve, two studies used online cut-off finding software, and one study used median value to determine the cut-off value. According to the reports,
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there were also differences in cut-off values. In order to apply these markers in the clinical setting, in future, it will be necessary to determine the ideal cut-off values.
In conclusion, NLR and CAR, but not PLR, are useful prognostic markers for esophageal cancer. Further prospective studies are required in order to confirm the results of this systematic review and meta-analysis.
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